Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Lucia Moletta

University of Padova, Italy

Title: Metastatic tumors to the pancreas: is surgery a therapeutic option for this rare clinical entity?

Biography

Biography: Lucia Moletta

Abstract

Statement of the Problem:

Pancreatic metastases (PM) from other tumors are rare and they account for approximately 1-2 % of all pancreatic malignancies.PM represent a therapeutic challenge: most patients present at diagnosis with a widespread disease while the finding of an isolated pancreatic lesion is far more uncommon. Even if in recent years a growing number of studies have reported successful pancreatic resection for PM, the role of surgery in this context remains undefined. The purpose of this study is to investigate the safety and efficacy of surgical resection in patients affected by PM.

Methodology & Theoretical Orientation:

We reviewed all patients with PM between January 1980 and December 2020 from a prospectively collected database. All enrolled patients had a histological diagnosis of PM. The following data were analyzed: basic demographics, characteristics of primary tumor, time interval between primary and secondary PM, symptoms, presence of extra pancreatic disease, surgical strategy, morbidity, mortality, length of ICU and hospital stay, neoadjuvant and adjuvant treatment, follow-up, disease-free survival and overall survival.  

Findings:

In the considered time-interval, 44 patients were observed in our Center for PM (M/F 22/22; median age 66 years, range 41-78). Renal cell carcinoma represented the most frequent primary tumor (n=19), followed by colorectal cancer (n=12), sarcoma (n=4), melanoma (n=4, lung cancer (n=2), schwannoma (n=1), gastric cancer (n=1), small bowel carcinoid tumor (n=1). Thirty-seven patients underwent surgery and pancreatic resection was feasible in 35 cases. Overall morbidity and mortality rates were 36% and 2%, respectively. Median OS and DSF survival were significantly longer for patients with PM from renal cancer when compared to other patients (p=0.008). At univariate and multivariate analysis, the renal origin of PM was the only independent prognostic factors for survival.

Conclusions:

Surgery for PM is safe and effective, especially for PM of renal origin.